ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Spirit 2: Final Analysis of an NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Stephen O'Brien
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Stephen O'Brien
0 views
January 2, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Scientific Session 1: Top Scoring Abstracts 2018
15:24
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Skeletal Muscle Toxicity Associated with Tyrosine Kinase Inhibitor T…

Feat. L. Janssen
16:25
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Spirit 2: Final Analysis of an NCRI Randomised Study Comparing Dasat…

Feat. S. O'Brien
16:00
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Nilotinib vs. Nilotinib Plus Interferon α Induction and Nilotinib or…

Feat. A. Hochhaus